The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis

Molecular and Cellular Biology

Volumn 25, Issue 6, 2005, Pages 2395-2405

  Cardone, Monica ^a   Kandilci, Ayten ^a   Carella, Cintia ^a   Nilsson, Jonas A ^a   Brennan, Jennifer A ^a   Sirma, Sema ^b   Ozbek, Ugur ^b   Boyd, Kelli ^a   Cleveland, John L ^a   Grosveld, Gerard C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR ETS;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBODY PRODUCTION; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; FLUORESCENCE ACTIVATED CELL SORTING; LEUKEMIA; NONHUMAN; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TEL2 ONCOGENE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL PROLIFERATION; CHILD; DNA-BINDING PROTEINS; FEMALE; HUMANS; LEUKEMIA, B-CELL, ACUTE; MALE; MICE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENE PROTEINS C-MYC; SUPPRESSION, GENETIC; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

DROMAIUS NOVAEHOLLANDIAE; MUS MUSCULUS;

EID: 20144385108     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.6.2395-2405.2005     Document Type: Article

References (49)

1. Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538.
2. Alexander, W. S., J. W. Schrader, and J. M. Adams. 1987. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice. Mol. Cell. Biol. 7:1436-1444.
3. ar-Rushdi, A., K. Nishikura, J. Erikson, R. Watt, G. Rovera, and C. M. Croce. 1983. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 222:390-393.
4. Bates, S., A. C. Phillips, P. A. Clark, F. Stott, G. Peters, R. L. Ludwig, and K. H. Vousden. 1998. p14ARF links the tumour suppressors RB and p53. Nature 395:124-125.
5. Baudino, T. A., K. H. Maclean, J. Brennan, E. Parganas, C. Yang, A. Aslanian, J. A. Lees, C. J. Sherr, M. F. Roussel, and J. L. Cleveland. 2003. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol. Cell 11:905-914.
6. Blyth, K., A. Terry, M. O'Hara, E. W. Baxter, M. Campbell, M. Stewart, L. A. Donehower, D. E. Onions, J. C. Neil, and E. R. Cameron. 1995. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10:1717-1723.
7. Chakrabarti, S. R., and G. Nucifora. 1999. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem. Biophys. Res. Commun. 264:871-877.
8. Chen, H. M., and L. M. Boxer. 1995. Pi 1 binding sites are negative regulators of bcl-2 expression in pre-B cells. Mol. Cell. Biol. 15:3840-3847.
9. DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J. R. Nevins. 1997. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA 94:7245-7250.
10. Dittmer, J., and A. Nordheim. 1998. Ets transcription factors and human disease. Biochim. Biophys. Acta 1377:F1-11.
11. Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658-2669.
12. L or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 21:5063-5070.
13. Golub, T. R., G. F. Barker, K. Stegmaier, and D. G. Gilliland. 1997. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr. Top. Microbiol. Immunol. 220:67-79.
14. Grillot, D. A., R. Merino, J. C. Pena, W. C. Fanslow, F. D. Finkelman, C. B. Thompson, and G. Nunez. 1996. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J. Exp. Med. 183:381-391.
15. Gu, X., B. H. Shin, Y. Akbarali, A. Weiss, J. Boltax, P. Oettgen, and T. A. Libermann. 2001. Tel-2 is a novel transcriptional repressor related to the Ets factor Te1/ETV-6. J. Biol. Chem. 276:9421-9436.
16. Hayday, A. C., S. D. Gillies, H. Saito, C. Wood, K. Wiman, W. S. Hayward, and S. Tonegawa. 1984. Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature 307:334-340.
17. Irvin, B. J., L. D. Wood, L. Wang, R. Fenrick, C. G. Sansam, G. Packham, M. Kinch, E. Yang, and S. W. Hiebert. 2003. TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-XL. J. Biol. Chem. 278:46378-46386.
18. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.
19. Kawagoe, H., M. Potter, J. Ellis, and G. C. Grosveld. 2004. TEL2, an ETS factor expressed in human leukemia, regulates monocytic differentiation of U937 cells and blocks the inhibitory effect of TEL1 on ras-induced cellular transformation. Cancer Res. 64:6091-6100.
20. Koizumi, Y., S. Tanaka, R. Mou, H. Koganei, A. Kokawa, R. Kitamura, H. Yamauchi, K. Ookubo, T. Saito, S. Tominaga, K. Matsumura, H. Shimada, N. Tsuchida, and H. Sekihara. 1997. Changes in DNA copy number in primary gastric carcinomas by comparative genomic hybridization. Clin. Cancer Res. 3:1067-1076.
21. Langdon, W. Y., A. W. Harris, S. Cory, and J. M. Adams. 1986. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47:11-18.
22. Lopez, R. G., C. Carron, C. Oury, P. Gardellin, O. Bernard, and J. Ghysdael. 1999. TEL is a sequence-specific transcriptional repressor. J. Biol. Chem. 274:30132-30138.
23. Mavrothalassitis, G., and J. Ghysdael. 2000. Proteins of the ETS family with transcriptional repressor activity. Oncogene 19:6524-6532.
24. Mazurenko, N., M. Attaleb, T. Gritsko, L. Semjonova, L. Pavlova, O. Sakharova, and F. Kisseyov. 1999. High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol. Rep. 6:859-863.
25. Mitelman, F., F. Mertens, and B. Johansson. 1997. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15(Spec.):417-474.
26. Moore, E., H. Magee, J. Coyne, T. Gorey, and P. A. Dervan. 1999. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS. J. Pathol. 187:403-409.
27. Oikawa, T., and T. Yamada. 2003. Molecular biology of the Ets family of transcription factors. Gene 303:11-34.
28. Persons, D. A., J. A. Allay, E. R. Allay, R. J. Smeyne, R. A. Ashmun, B. P. Sorrentino, and A. W. Nienhnis. 1997. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90:1777-1786.
29. Poirel, H., R. G. Lopez, V. Lacronique, V. Della Valle, M. Mauchauffe, R. Berger, J. Ghysdael, and O. A. Bernard. 2000. Characterization of a novel ETS gene, TELB, encoding a protein structurally and functionally related to TEL. Oncogene 19:4802-4806.
30. Potter, M., A. Buijs, B. Kreider, L. V. Rompaey, and G. Grosveld. 2000. Identification and characterization of a new human ETS-family transcription factor, TEL2, that is expressed in hematopoietic tissues and can associate with TEL1/ETV6. Blood 95:3341-3348.
31. Rabbitts, T. H. 1994. Chromosomal translocations in human cancer. Nature 372:143-149.
32. Ink4a loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc. Natl. Acad. Sci. USA 98:9654-9659.
33. Raynaud, S., H. Cave, M. Baens, C. Bastard, V. Cacheux, J. Grosgeorge, C. Guidal-Giroux, C. Guo, E. Vilmer, P. Marynen, and B. Grandchamp. 1996. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 87:2891-2899.
34. Romana, S. P., H. Poirel, M. Leconiat, M. A. Flexor, M. Mauchauffe, P. Jonveaux, E. A. Macintyre, R. Berger, and O. A. Bernard. 1995. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86:4263-4269.
35. Saffran, D. C., E. A. Faust, and O. N. Witte. 1992. Establishment of a reproducible culture technique for the selective growth of B-cell progenitors. Curr. Top. Microbiol. Immunol. 182:37-43.
36. Sample, J. T. Burkitt lymphoma. In J. H. Tselis (ed.), Epstein-Barr virus, in press. Marcel Dekker, New York, N.Y.
37. Sanchez-Beato, M., A. Sanchez-Aguilera, and M. A. Piris. 2003. Cell cycle deregulation in B-cell lymphomas. Blood 101:1220-1235.
38. Schmitt, C. A., and S. W. Lowe. 2002. Apoptosis and chemoresistance in transgenic cancer models. J. Mol. Med. 80:137-146.
39. Schmitt, C. A., M. E. McCurrach, E. de Stanchina, R. R. Wallace-Brodeur, and S. W. Lowe. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:2670-2677.
40. Schmitt, C. A., R. R. Wallace-Brodeur, C. T. Rosenthal, M. E. McCurrach, and S. W. Lowe. 2000. DNA damage responses and chemosensitivity in the Eμ-myc mouse lymphoma model. Cold Spring Harbor Symp. Quant. Biol. 65:499-510.
41. Sevilla, L., A. Zaldumbide, P. Pognonec, and K. E. Boulukos. 2001. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NF-κB, STAT and AP1 transcription factor families. Histol. Histopathol. 16:595-601.
42. Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
43. Strasser, A., A. W. Harris, M. L. Bath, and S. Cory. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333.
44. Tognon, C., S. R. Knezevich, D. Huntsman, C. D. Roskelley, N. Melnyk, J. A. Mathers, L. Becker, F. Carneiro, N. MacPherson, D. Horsman, C. Poremba, and P. H. Sorensen. 2002. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2:367-376.
45. Van Rompaey, L., W. Dou, A. Buijs, and G. Grosveld. 1999. Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components. Neoplasia 1:526-536.
46. Wang, L., F. Kuo, Y. Fujiwara, D. Gilliland, T. Golub, and S. Orkin. 1997. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J. 16:4374-4383.
47. Wang, L., W. Swat, Y. Fujiwara, D. Gilliland, T. Golub, and S. Orkin. 1998. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12:2392-2402.
48. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433.
49. Zindy, F., D. E. Quelle, M. F. Roussel, and C. J. Sherr. 1997. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15:203-211.